BLA 103979 · Genzyme
Fabrazyme
Agalsidase Beta · Intravenous · Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Apr 24, 2003
Approved uses
5
Original approval plus efficacy supplements
Registered trials
25
8 Phase 3, 1 recruiting
FAERS reports
9,357
4,797 serious, 703 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate FABRAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur. [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...
What it is approved for
From the label in effect Aug 22, 2025.
FABRAZYME ® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease. FABRAZYME is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease. ( 1 )
Mechanism: FABRAZYME (agalsidase beta) provides an exogenous source of α-galactosidase A in Fabry disease patients. Agalsidase beta is internalized and transported into lysosomes where it exerts enzymatic activity and reduces accumulated GL-3.
Therapeutic areas: Cardiovascular and metabolic · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 11, 2021 Supplement 5309 · Efficacy OrphanLetterLabelReview
- Sep 29, 2006 Supplement 5066 · Efficacy OrphanLetterLabel
- Sep 29, 2006 Supplement 5058 · Efficacy OrphanLetterLabel
- Sep 29, 2006 Supplement 5065 · Efficacy OrphanLabelLetter
- Apr 24, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
2 products under this application
- FABRAZYME · AGALSIDASE BETA 35MG/VIAL · VIAL, INTRAVENOUS · Prescription
- FABRAZYME · AGALSIDASE BETA 5MG/VIAL · VIAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Agalsidase Beta" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05280548 · 104 participants · Start May 3, 2022 · Primary completion May 22, 2026
Drug: Venglustat (GZ402671); Agalsidase alfa and 2 more · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 54 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00074984 · 82 participants · Start Feb 2001 · Primary completion Jan 2004
Drug: Fabrazyme (agalsidase beta); Placebo · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 26 sites in all
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionPivotal-lookingCompleted
ProtalixIndustry
NCT02795676 · 78 participants · Start Jun 2016 · Primary completion Oct 2021
Drug: PRX-102 (pegunigalsidase alfa); agalsidase beta · For: Fabry Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Orange, California · 29 sites in all
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT01218659 · 68 participants · Start Sep 8, 2011 · Primary completion May 27, 2014
Drug: migalastat hydrochloride; agalsidase · For: Fabry Disease
Sites: Los Angeles, California; Aurora, Colorado; Decatur, Georgia · 25 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00081497 · 67 participants · Start Jan 2004 · Primary completion Sep 2005
Drug: agalsidase beta · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 25 sites in all
- A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry DiseasePivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00074971 · 58 participants · Start Oct 1999
Drug: Fabrazyme (agalsidase beta) · For: Fabry Disease
Sites: Los Angeles, California; San Francisco, California; Coral Springs, Florida · 20 sites in all
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT01997489 · 39 participants · Start Sep 2001 · Primary completion Sep 2013
Drug: Enzyme replacement · For: Fabry Disease
Sites: Copenhagen, Denmark · 2 sites in all
- Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry DiseaseStatus unknown
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00487630 · 34 participants (planned) · Start Jun 2005
Drug: recombinant alpha-galactosidase A · For: Fabry Disease
Sites: Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia526
- pain514
- malaise497
- chills481
- nausea477
- fatigue433
- dyspnoea428
- headache382
- vomiting378
- weight decreased350
- pain in extremity321
- infusion related reaction301
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 259 |
| 2005 | 312 |
| 2006 | 197 |
| 2007 | 169 |
| 2008 | 181 |
| 2009 | 170 |
| 2010 | 187 |
| 2011 | 193 |
| 2012 | 175 |
| 2013 | 313 |
| 2014 | 782 |
| 2015 | 590 |
| 2016 | 473 |
| 2017 | 588 |
| 2018 | 508 |
| 2019 | 468 |
| 2020 | 331 |
| 2021 | 480 |
| 2022 | 630 |
| 2023 | 642 |
| 2024 | 619 |
| 2025 | 575 |
| 2026 | 515 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fabrazyme (Agalsidase Beta)
2024 spending
$41.3M
Beneficiaries
110
2,032 claims
Per beneficiary
$375,136
$4,731.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,364,445 |
| 2021 | $33,112,272 |
| 2022 | $37,333,578 |
| 2023 | $39,532,208 |
| 2024 | $41,264,991 |
Part B: Fabrazyme (Agalsidase Beta) · HCPCS J0180
2024 spending
$66.3M
Beneficiaries
203
3,596 claims
Per beneficiary
$326,823
2024 ASP limit $220.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $50,489,089 |
| 2021 | $52,527,145 |
| 2022 | $62,283,822 |
| 2023 | $66,506,215 |
| 2024 | $66,345,021 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M, Bultas J, Waldek S, et al. · Ann Intern Med 2007 · Multicenter Study, Randomized Controlled Trial
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL, Goker-Alpan O, Wilcox WR, et al. · J Med Genet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature.
Pisani A, Bruzzese D, Sabbatini M, et al. · Genet Med 2017 · Meta-Analysis, Systematic Review
- Why systematic literature reviews in Fabry disease should include all published evidence.
Elliott PM, Germain DP, Hilz MJ, et al. · Eur J Med Genet 2019 · Systematic Review
- A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.
Ren H, Zhang W, Ouyang Y, et al. · Orphanet J Rare Dis 2025 · Multicenter Study, Clinical Trial, Phase IV
- A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4ߙweeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
Holida M, Linhart A, Pisani A, et al. · J Inherit Metab Dis 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.